Preview

Вестник трансплантологии и искусственных органов

Расширенный поиск

ПОВТОРНАЯ ТРАНСПЛАНТАЦИЯ ПОЧКИ

https://doi.org/10.15825/1995-1191-2016-4-157-169

Полный текст:

Аннотация

В настоящее время для большинства пациентов с терминальной почечной недостаточностью пересадка почки является наилучшим методом заместительной почечной терапии (ЗПТ), который значительно увеличивает продолжительность и качество жизни. Прогресс в области органного донорства, хирургической техники, трансплантационной иммунологии и иммуносупрессии существенно улучшил непосредственные результаты трансплантаций. При этом отдаленная выживаемость трансплантатов в течение последних двух десятилетий практически не изменилась. Несоответствие между показателями отдаленной выживаемости реципиентов и трансплантатов привело к увеличению количества пациентов, утративших функцию пересаженной почки. Для большинства из них повторная трансплантация представляется оптимальным вариантом продолжения ЗПТ, хотя и сопряжена c большей частотой осложнений. При этом рекомендации по проведению ретрансплантации почки, основанные на принципах доказательной медицины, до сих пор отсутствуют. Настоящий обзор основан на материале 100 научных публикаций, посвященных различным аспектам планирования и выполнения ретрансплантации почки.

Об авторе

А. И. Сушков
ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России
Россия

Адрес: 123182, Москва, ул. Щукинская, д. 1. Тел. (916) 177-89-24



Список литературы

1. . Kramer A et al. Renal replacement therapy in Europe: a summary of the 2013 ERA- EDTA Registry Annual Report with a focus on diabetes mellitus. Clin. Kidney J. 2016; 9 (3): 457–469.

2. Ojo A. et al. Prognosis after primary renal transplant failure and the benefi cial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation. 1998; 66 (12): 1651–1659.

3. Rao PS et al. Evaluating the survival benefi t of kidney retransplantation. Transplantation. 2006; 82 (5): 669–674.

4. A rndorfer JA et al. Time to fi rst graft loss as a risk factor for second renal allograft loss. Transplant. Proc. 2001; 33 (1–2): 1188–1189.

5. Pan chal H et al. Expanded criteria donor kidneys for retransplantation United Network for Organ Sharing update: proceed with caution. Transpl. Int. 2015; 28 (8): 990– 999.

6. El-A groudy AE et al. Living-donor kidney retransplantation: risk factors and outcome. BJU Int. 2004; 94 (3): 369–373.

7. Tsape pas DS et al. Preformed donor-specifi c antibodies and risk of antibody- mediated rejection in repeat renal transplantation. Transplantation. 2014; 97 (6): 642– 647.

8. Heaphy EL et al. Risk factors for retransplant kidney recipients: relisting and outcomes from patients’ primary transplant. Am. J. Transplant. 2014; 14 (6): 1356–13567.

9. Marcen R et al. Evolution of rejection rates and kidney graft survival: a historical analysis. Transplant. Proc. 2009; 41 (6): 2357–2359.

10. El-Zogh by ZM et al. Identifying specifi c causes of kidney allograft loss. Am. J. Transplant. 2009; 9 (3): 527– 535.

11. Chang SH et al. Trends in kidney transplantation in Australia and New Zealand, 1993–2004. Transplantation. 2007; 84 (5): 611–618.

12. Hoogland E R et al. Kidney transplantation from donors after cardiac death: uncontrolled versus controlled donation. Am. J. Transplant. 2011; 11 (7): 1427–1434.

13. CTS Outcome Graphs, K-14103E-0216, Editor 2016, Collaborative Transplant Study: http://www.ctstransplant.org/public/graphics/archive.shtml.

14. Lamb KE, Lo dhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am. J. Transplant. 2011; 11 (3): 450–462.

15. Nankivell BJ et al. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 2003; 349 (24): 2326–2333.

16. Chapman JR, O ‘Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J. Am. Soc. Nephrol. 2005; 16 (10): 3015–3026.

17. Gaston RS et a l. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010; 90 (1): 68–74.

18. Gourishankar S et al. Pathological and clinical characterization of the ‘troubled transplant’: data from the De- KAF study. Am. J. Transplant. 2010; 10 (2): 324–330.

19. Josephson MA. La te kidney dysfunction in a kidney transplant recipient. Clin. J. Am. Soc. Nephrol. 2014; 9 (3): 590–597.

20. Matas AJ et al. O PTN/SRTR 2013 Annual Data Report: kidney. Am. J. Transplant. 2015; 15 Suppl 2: 1–34.

21. US Renal Data Syst em: USRDS 2007 Annual Data Report, 2007, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda.

22. Annual Report 2014 / Eurotransplant International Foundation, 2015, Eurotransplant Foundation: Leiden.

23. Готье СВ, Мойсюк Я Г, Ибрагимова ОС. Тенденции развития органного донорства и трансплантации в Российской Федерации в 2006–2008 гг. Сообщение (по данным регистра Российского трансплантологического общества). Вестник трансплантологии и искусственных органов. 2009; 11 (3): 8–16. Gautier SV, Mojsyuk YaG, Ibragimova OS. Tendencii razvitiya organnogo donorstva i transplantacii v Rossijskoj Federacii v 2006–2008 gg. Soobshchenie I (po dannym registra Rossijskogo transplantologicheskogo obshchestva). Vestnik transplantologii i iskusstvennyh organov. 2009; 11 (3): 8–16.

24. Состояние органного донорства и трансплантации в России по итогам 2009 г. (по данным регистра Российского трансплантологического общества). Трансплантология 2009: Итоги и перспективы. Том I. Под ред. С.В. Готье. М.–Тверь: Триада, 2010: 8–20. Sostoyanie organnogo donorstva i transplantatsii v Rossii po itogam 2009 g. (po dannym registra Rossiyskogo transplantologicheskogo obshchestva). Transplantologiya 2009: Itogi i perspektivy. Tom I. Pod red. S.V. Gautier. M.–Tver’: Triada, 2010: 8–20.

25. Развитие органного донорства и трансплантации в Российской Федерации в 2006–2010 годах (III сообщение регистра Российского трансплантологического общества). Трансплантология: итоги и перспективы. Том II. 2010 год. Под ред. С.В. Готье. М.–Тверь: Триада, 2011: 17–32. Razvitie organnogo donorstva i transplantacii v Rossijskoj Federacii v 2006–2010 godah (III soobshchenie registra Rossijskogo transplantologicheskogo obshchestva). Transplantologija: itogi i perspektivy. Tom II. 2010 god. Pod red. S.V. Gautier. M.–Tver’: Triada, 2011: 17–32.

26. О рганное донорство и трансплантация в Российской Федерации в 2011 году (IV сообщение Национального регистра Российского трансплантологического общества). Трансплантология: итоги и перспективы. Том III. 2011 год. Под ред. С.В. Готье. М.–Тверь: Триада, 2012: 13–38. Organnoe donorstvo i transplantacija v Rossijskoj Federacii v 2011 godu (IV soobshchenie Nacional’nogo registra Rossijskogo transplantologicheskogo obshchestva). Transplantologija: itogi i perspektivy. Tom III. 2011 god. Pod red. S.V. Gautier. M.–Tver’: Triada, 2012: 13–38.

27. Орган ное донорство и трансплантация в Российской Федерации в 2012 году (V сообщение регистра Российского трансплантологического общества). Трансплантология: итоги и перспективы. Том IV. 2012 год. Под ред. С.В. Готье. М.– Тверь: Триада, 2013: 7–28. Organnoe donorstvo i transplantacija v Rossijskoj Federacii v 2012 godu (V soobshchenie registra Rossijskogo transplantologicheskogo obshchestva).

28. Transplantologija: itogi i perspektivy. Tom IV. 2012 god. Pod red. S.V. Gautier. M.–Tver’: Triada, 2013: 7–28.

29. Донорство и трансплантация органов в Российской Федерации в 2013 году (VI сообщение регистра Российского трансплантологического общества). Трансплантология: итоги и перспективы. Том V. 2013 год. Под ред. С.В. Готье. М.– Тверь: Триада, 2014: 29–56. Donorstvo i transplantacija organov v Rossijskoj Federacii v 2013 godu (VI soobshchenie registra Rossijskogo transplantologicheskogo obshchestva). Transplantologija: itogi i perspektivy. Tom V. 2013 god. Pod red. S.V. Gautier. M.–Tver’: Triada, 2014: 29–56.

30. Донорство и т рансплантация органов в Российской Федерации в 2014 году (VII сообщение регистра Российского трансплантологического общества). Трансплантология: итоги и перспективы. Том VI. 2014 год. Под ред. С.В. Готье. М.– Тверь: Триада, 2015: 43–76. Donorstvo i transplantacija organov v Rossijskoj Federacii v 2014 godu (VII soobshchenie registra Rossijskogo transplantologicheskogo obshchestva). Transplantologija: itogi i perspektivy. Tom VI. 2014 god. Pod red. S.V. Gautier. M.–Tver’: Triada, 2015: 43–76.

31. Томилина НА, Бикбов БТ. Состояние за местительной почечной терапии при хронической почечной недостаточности в России в 1998–2011 гг. (по данным регистра Российского диализного общества). Вестник трансплантологии и искусственных органов. 2015; 17 (1): 35–38. Tomilina NA, Bikbov BT. Sostoyanie zamestitel’noj pochechnoj terapii pri hronicheskoj pochechnoj nedostatochnosti v Rossii v 1998–2011 gg. (po dannym registra Rossijskogo dializnogo obshchestva). Vestnik transplantologii i iskusstvennyh organov. 2015; 17 (1): 35–38.

32. Gill JS et al. Mortality after kidney tr ansplant failure: the impact of non- immunologic factors. Kidney Int. 2002; 62 (5): 1875–1883.

33. Kaysi S et al. Chronic renal failure comp lications and management in kidney transplanted and nontransplanted patients. Transplant. Proc. 2012; 44 (10): 2997–3000.

34. Marcen R et al. Achieving chronic kidney d isease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain. Transplantation. 2009; 87 (9): 1340–1346.

35. Ansell D et al. Chronic renal failure in ki dney transplant recipients. Do they receive optimum care?: data from the UK renal registry. Am. J. Transplant. 2007; 7 (5): 1167– 1176.

36. British Transplantation Society. United King dom Guidelines. Management of the failing kidney transplant. 2014; Available from: http://www.bts.org.uk/Documents/Guidelines/Active/Failing%20Graft%20Guideline.pdf

37. Johnston O et al. Nephrectomy after transpla nt failure: current practice and outcomes. Am. J. Transplant. 2007; 7 (8): 1961–1967.

38. Trofe J et al. Analysis of factors that infl u ence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am. J. Transplant. 2005; 5 (4 Pt 1): 775–780.

39. Tillou X et al. De novo kidney graft tumors: r esults from a multicentric retrospective national study. Am. J. Transplant. 2012; 12 (12): 3308–3315.

40. Langone AJ, Chuang P. The management of the failed renal allograft: an enigma with potential consequences. Semin. Dial. 2005; 18 (3): 185–187.

41. Lorenzo V et al. Ablation of irreversibly rejected renal allograft by embolization with absolute ethanol: a new clinical application. Am. J. Kidney Dis. 1993; 22 (4): 592–595.

42. Delgado P et al. Intolerance syndrome in failed renal allografts: incidence and effi cacy of percutaneous embolization. Am. J. Kidney Dis. 2005; 46 (2): 339–344.

43. Chong X et al. Safety and effectiveness of percutaneous embolization for late failed renal allograft in patients with graft intolerance syndrome. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011; 33 (1): 76–79.

44. Neschis DG et al. Intraoperative coil embolization reduces transplant nephrectomy transfusion requirement. Vasc. Endovascular. Surg. 2007; 41 (4): 335–338.

45. Scornik JC, Kriesche HU. Human leukocyte antigen sen sitization after transplant loss: timing of antibody detection and implications for prevention. Hum. Immunol. 2011; 72 (5): 398–401.

46. Del Bello A et al. Anti-human leukocyte antigen immun ization after early allograft nephrectomy. Transplantation. 2012; 93 (9): 936–941.

47. Marrari M., Duquesnoy RJ. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transpl. Immunol. 2010; 22 (3–4): 105– 109.

48. Heinemann FM et al. Characterization of anti-HLA antibodies eluted from explanted renal allografts. Clin. Transpl. 2006: 371–378.

49. Casey MJ et al. Prolonged immunosuppression preserves non sensitization status after kidney transplant failure. Transplantation. 2014; 98 (3): 306–311.

50. Jassal SV et al. Continued transplant immunosuppression ma y prolong survival after return to peritoneal dialysis: results of a decision analysis. Am. J. Kidney Dis. 2002; 40 (1): 178–183.

51. Pham PT, Pham PC. Immunosuppressive management of dialysis patients with recently failed transplants. Semin. Dial. 2011; 24 (3): 307–313.

52. Pham PT et al. Management of patients with a failed kidney t ransplant: Dialysis reinitiation, immunosuppression weaning, and transplantectomy. World J. Nephrol. 2015; 4 (2): 148–159.

53. Cardarelli F et al. Prevalence and signifi cance of anti-HLA a nd donor-specific antibodies long-term after renal transplantation. Transpl. Int. 2005; 18 (5): 532–540.

54. Lefaucheur C et al. IgG Donor-Specifi c Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. J. Am. Soc. Nephrol. 2016; 27 (1): 293–304.

55. Loupy A et al. Complement-binding anti-HLA antibodies and kidne y-allograft survival. N. Engl. J. Med. 2013; 369 (13): 1215–1226.

56. Arnold ML et al. Donor-specifi c HLA antibodies: evaluating the r isk for graft loss in renal transplant recipients with isotype switch from complement fi xing IgG1/IgG3 to noncomplement fi xing IgG2/IgG4 anti-HLA alloantibodies. Transpl. Int. 2014; 27 (3): 253–261.

57. Thammanichanond D et al. Role of Pretransplant Complement-fi xing Donor-specifi c Antibodies Identifi ed by C1q Assay in Kidney Transplantation. Transplant. Proc. 2016; 48 (3): 756–760.

58. Crespo E et al. Pre-transplant donor-specifi c T-cell alloreactivit y is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving T-cell depleting induction therapy. PLoS One. 2015; 10 (2): e0117618.

59. Lucia M et al. Preformed circulating HLA-specifi c memory B cells p redict high risk of humoral rejection in kidney transplantation. Kidney Int. 2015; 88 (4): 874– 887.

60. House AA et al. Re-exposure to mismatched HLA class I is a signifi c ant risk factor for graft loss: multivariable analysis of 259 kidney retransplants. Transplantation. 2007; 84 (6): 722–728.

61. Barnett AN et al. Tailored desensitization strategies in AB0 blood g roup antibody incompatible renal transplantation. Transpl. Int. 2014; 27 (2): 187–196.

62. Manook MBL, Osei-Bordom D, Sandhu B, Maggs T, Shaw O, Kessaris N, Sha h S et al. Deceased Donor AB0- Incompatible Kidney Transplantation Has the Potential to Reduce Blood Group Disparity. Am. J. Transplant. 2016; 16 (3 suppl).

63. Heidt S et al. The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients. Transpl. Immunol. 2015; 33 (2): 51–57.

64. Jordan SC et al. Progress in Desensitization of the Highly HLA Sensiti zed Patient. Transplant. Proc. 2016; 48 (3): 802–805.

65. Montgomery RA et al. Desensitization in HLA-incompatible kidney recipie nts and survival. N. Engl. J. Med. 2011; 365 (4): 318–326.

66. Halawa A. The third and fourth renal transplant; technically challenging , but still a valid option. Ann. Transplant. 2012; 17 (4): 125–132.

67. Nghiem DD. Orthotopic kidney retransplantation in simultaneous pancreas k idney transplant patients with renal failure. Transplant. Proc. 2008; 40 (10): 3609–3610.

68. Chedid MF et al. Renal retransplantation after kidney and pancreas transpl antation using the renal vessels of the failed allograft: pitfalls and pearls. Clin. Transplant. 2014; 28 (6): 669–674.

69. Mazzucchi E et al. Surgical aspects of third and subsequent renal transplan ts performed by the extraperitoneal access. Transplantation. 2006; 81 (6): 840–844.

70. Hagan C, Hickey DP, Little DM. A single-center study of the technical aspect s and outcome of third and subsequent renal transplants. Transplantation. 2003; 75 (10): 1687–1691.

71. Nourbala MH, Ghaheri H, Kardavani B. Our experience with third renal transpla ntation: results, surgical techniques and complications. Int. J. Urol. 2007; 14 (12): 1057–1059; discussion 1059.

72. Musquera M et al. Orthotopic kidney transplantation: an alternative surgical t echnique in selected patients. Eur. Urol. 2010; 58 (6): 927–933.

73. Kienzl-Wagner K et al. Single-center experience with third and fourth kidney tr ansplants. Transpl. Int. 2011; 24 (8): 780–786.

74. Koch MJ. Considerations in retransplantation of the failed renal allograft recip ient. Adv. Chronic Kidney Dis. 2006; 13 (1): 18–28.

75. Sureshkumar KK et al. Steroid maintenance in repeat kidney transplantation: infl u ence of induction agents on outcomes. Saudi J. Kidney Dis. Transpl. 2014; 25 (4): 741– 749.

76. Schold J et al. Clinical outcomes associated with induction regimens among retrans plant kidney recipients in the United States. Transplantation. 2015; 99 (6): 1165– 1171.

77. Rodriguez-Reimundes E et al. Retreatment by antithymocyte globulin for second kidne y transplantation: efficacy, tolerance and safety. Transpl. Immunol. 2013; 28 (1): 6–8.

78. Klem P et al. Reduced dose rabbit anti-thymocyte globulin induction for prevention o f acute rejection in highrisk kidney transplant recipients. Transplantation. 2009; 88 (7): 891–896.

79. Gurk-Turner C et al. Thymoglobulin dose optimization for induction therapy in high ri sk kidney transplant recipients. Transplantation. 2008; 85 (10): 1425–1430.

80. Thibaudin D et al. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol. Dial. Transplant. 1998; 13 (3): 711–715.

81. Hellemans R et al. Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal T ransplants: Five- Year Follow-up of a Randomized Study. Am. J. Transplant. 2015; 15 (7): 1923–1932.

82. Barnett AN, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transpl. Int. 2013; 26 (6): 563–575.

83. Clatworthy MR et al. B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med. 2009; 360 (25): 2683–2685.

84. Tyden G et al. A randomized, doubleblind, placebocontrolled, study of single-dose rituxim ab as induction in renal transplantation. Transplantation. 2009; 87 (9): 1325– 1329.

85. van den Hoogen MW et al. Rituximab as induction therapy after renal transplantation: a rand omized, doubleblind, placebo-controlled study of effi cacy and safety. Am. J. Transplant. 2015; 15 (2): 407–416.

86. Abu Jawdeh BG et al. Desensitization in kidney transplantation: review and future perspectiv es. Clin. Transplant. 2014; 28 (4): 494–507.

87. Jordan SC, Choi J, Vo A. Kidney transplantation in highly sensitized patients. Br. Med. Bull. 2015; 114 (1): 113–125.

88. Legendre C et al. Eculizumab in renal transplantation. Transplant. Rev. (Orlando). 2013; 27 (3 ): 90–92.

89. Mujtaba MA et al. Early steroid withdrawal in repeat kidney transplantation. Clin. J. Am. Soc. Nephrol. 2011; 6 (2): 404–411.

90. Ott U et al. Renal retransplantation: a retrospective monocentric study. Transplant. Proc. 2008; 40 (5): 1345–1348.

91. Vincenti F et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am. J. Transplant. 2008; 8 (2): 307–316.

92. Kaufman DB et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney tr ansplantation: comparison with basiliximab induction – long-term results. Am. J. Transplant. 2005; 5 (10): 2539–2548.

93. Tan HP et al. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation. Transplant. Proc. 2005; 37 (10): 4235–4240.

94. Kandaswamy R et al. A prospective randomized trial of steroid-free maintenance regimens in kidney tra nsplant recipients – an interim analysis. Am. J. Transplant. 2005; 5 (6): 1529–1536.

95. Rostaing L et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and dac lizumab induction in renal transplantation. Transplantation. 2005; 79 (7): 807–814.

96. Alloway RR et al. A prospective, pilot study of early corticosteroid cessation in high- immunologic-risk patients: the Cincinnati experience. Transplant. Proc. 2005; 37 (2): 802–803.

97. Khwaja K et al. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transpla ntation. 2004; 78 (9): 1397–1399.

98. Rao PS, Schaubel DE, Saran R. Impact of graft failure on patient survival on dialysis: a comparison of tra nsplant-naive and post-graft failure mortality rates. Nephrol. Dial. Transplant. 2005; 20 (2): 387–391.

99. Marcen R et al. Renal transplant recipient outcome after losing the fi rst graft. Transplant. Proc. 2003; 35 (5): 1679–1681.

100. ANZDATA Registry. 38th Report, Chapter 8: Transplantation. Australia and New Zeland Dialysis and Transplant Registry, 2016: Adelaide, Australia.

101. Астахов ПВ. Ретрансплантация трупной почки у больных с терминальной стадией хронической почечной недостаточ ности: Автореф. дис. ... канд. мед. наук. М., 1997. Astahov PV. Retransplantaciya trupnoj pochki u bol’nyh s terminal’noj stadiej hronicheskoj pochechnoj nedostatochnosti: Avtoref. dis. ... kand. med. nauk. M., 1997.


Для цитирования:


Сушков А.И. ПОВТОРНАЯ ТРАНСПЛАНТАЦИЯ ПОЧКИ. Вестник трансплантологии и искусственных органов. 2016;18(4):157-169. https://doi.org/10.15825/1995-1191-2016-4-157-169

For citation:


Sushkov A.I. REPEAT KIDNEY TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2016;18(4):157-169. (In Russ.) https://doi.org/10.15825/1995-1191-2016-4-157-169

Просмотров: 748


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)